$35.5M
+$35.5M this year1 filing since 2026 · latest Equity filed
CoreMap is a medical device company developing a high-density electrophysiology mapping system for atrial fibrillation. Its catheter uses a dense array of micro-scale electrodes to capture highly localized, high-fidelity electrograms, and its analytics software applies algorithms to that data to identify the drivers of AF. The goal is to let electrophysiologists target ablation precisely rather than treating AF empirically. The company received FDA Investigational Device Exemption approval for its INvENI map-guided AF ablation study and the technology is currently limited to investigational use.
What sets it apart
Micro-scale electrode density gives far greater spatial resolution and sample density than conventional mapping catheters, which is what makes algorithmic identification of AF drivers possible.
An investigational high-density mapping catheter with a dense array of micro-scale electrodes that records highly localized electrograms from atrial tissue, paired with an analytics platform that maps electrical activation during atrial fibrillation.
